Keiko Yamamoto
ORCID: 0000-0003-2343-2984
· 2 papers in corpus
nonrandomized-trial
2020
Interim results from the two-cohort, phase 2 KEYNOTE-100 study (NCT02674061) of 376 patients with previously treated advanced recurrent ovarian cancer (ROC) showed that pembrolizumab monotherapy was associated with an objective response rat…
case-report
2004
Müllerian adenosarcomas are rare tumors that occur in only 8% of uterine sarcomas (1). This tumor is an uncommon variant of mixed mesodermal tumor (MMT) of the uterus, and exhibits a malignant stroma and a benign glandular element. In usual…